A $2.5 Billion Commitment to Children with Cancer: Servier Acquires Day One Biopharmaceuticals

This blog is in the Top 25 M&A blogs worldwide according to Feedspot

In one of the most strategically focused pharma deals of early 2026, French pharmaceutical group Servier announced on March 6 its definitive agreement to acquire Nasdaq-listed Day One Biopharmaceuticals (DAWN) for $2.5 billion — at a stunning 68% premium to Day One's last closing price.

The Deal at a Glance

Servier will pay $21.50 per share in cash for all outstanding shares of Day One, representing a premium of approximately 68% over the March 5 closing price and an 86% premium to the one-month volume-weighted average price. The transaction will be funded entirely from Servier's existing cash reserves and is expected to close in Q2 2026, pending antitrust clearance and a majority tender of shares.

Why Day One?

Day One has carved out a unique niche: developing targeted cancer therapies for patients of all ages, with a particular focus on pediatric oncology — one of the most underserved and emotionally compelling areas in medicine. Its flagship product, Ojemda, is approved for pediatric low-grade glioma (a form of brain cancer) and generated $155.4 million in revenue in 2025, with 2026 guidance of $225–$250 million.​

Wedbush analyst Robert Driscoll had previously called Day One "an appealing acquisition target," noting both the successful Ojemda launch and the potential for additional label expansions. With a Phase 3 program targeting frontline therapy approval around 2028, Servier is essentially buying into a multi-year commercial growth curve.​

Strategic Fit for Servier

Servier, an independent pharma group governed by a non-profit foundation, has been executing on an ambitious 2030 strategy centered on oncology innovation and targeted therapies for high unmet medical needs. Acquiring Day One gives Servier a direct foothold in pediatric oncology in the US market, expands its pipeline from early-stage to Phase 3, and — critically — pairs Day One's scientific expertise with Servier's established global commercial infrastructure.

For M&A observers, this deal is a compelling illustration of a classic strategic bolt-on: a mid-sized, commercial-stage biotech with a validated asset, clear growth trajectory, and pipeline optionality acquired by a larger player willing to pay a meaningful control premium to accelerate its strategic agenda.